首页> 美国卫生研究院文献>Molecular Therapy >Dual Masking of Specific Negative Splicing Regulatory Elements Resulted in Maximal Exon 7 Inclusion of SMN2 Gene
【2h】

Dual Masking of Specific Negative Splicing Regulatory Elements Resulted in Maximal Exon 7 Inclusion of SMN2 Gene

机译:特定负拼接调控元件的双重掩盖导致SMN2基因最大外显子7包含。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Spinal muscular atrophy (SMA) is a fatal autosomal recessive disease caused by survival motor neuron (SMN) protein insufficiency due to SMN1 mutations. Boosting SMN2 expression is a potential therapy for SMA. SMN2 has identical coding sequence as SMN1 except for a silent C-to-T transition at the 6th nucleotide of exon 7, converting a splicing enhancer to a silencer motif. Consequently, most SMN2 transcripts lack exon 7. More than ten putative splicing regulatory elements (SREs) were reported to regulate exon 7 splicing. To investigate the relative strength of each negative SRE in inhibiting exon 7 inclusion, antisense oligonucleotides (AONs) were used to mask each element, and the fold increase of full-length SMN transcripts containing exon 7 were compared. The most potent negative SREs are at intron 7 (in descending order): ISS-N1, 3′ splice site of exon 8 (ex8 3′ss) and ISS+100. Dual-targeting AONs were subsequently used to mask two nonadjacent SREs simultaneously. Notably, masking of both ISS-N1 and ex8 3′ss induced the highest fold increase of full-length SMN transcripts and proteins. Therefore, efforts should be directed towards the two elements simultaneously for the development of optimal AONs for SMA therapy.
机译:脊髓性肌萎缩症(SMA)是一种致命的常染色体隐性遗传疾病,由SMN1突变引起的生存运动神经元(SMN)蛋白不足引起。增强SMN2表达是SMA的潜在疗法。 SMN2具有与SMN1相同的编码序列,除了在外显子7的第6个核苷酸处发生从C到T的沉默转换外,将剪接增强子转换为沉默子基序。因此,大多数SMN2转录物缺少外显子7。据报道,有十多个推定的剪接调控元件(SRE)调控外显子7剪接。为了研究每个负SRE在抑制第7外显子包涵体中的相对强度,使用反义寡核苷酸(AON)掩盖了每个元件,并比较了包含第7外显子的全长SMN转录本的倍数增加。最有效的阴性SRE位于内含子7(降序):ISS-N1,外显子8(ex8 3'ss)的3'剪接位点和ISS + 100。随后将双重靶向AON用来同时掩盖两个不相邻的SRE。值得注意的是,对ISS-N1和ex8 3's的屏蔽都导致全长SMN转录本和蛋白质的最高折叠倍数。因此,应同时针对这两个因素,以开发用于SMA治疗的最佳AON。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号